Statement: Patients must have healthy kidneys, liver and ovaries to participate in the primary trial.
Primary_evidence: Inclusion Criteria:   Histologically confirmed diagnosis of invasive triple negative breast cancer   Known status for the LCL161 predictive gene expression signature as determined during molecular pre-screening   Candidates for mastectomy or breast-conserving surgery   Primary tumor of greater than 20 mm and less than or equal to 50 mm diameter measured by imaging (previous Amendment #3 was tumor size greater than 10 mm)   Regional nodes N0-N2   Absence of distant metastatic disease   ECOG performance status 0-1   Adequate bone marrow function   Adequate liver function and serum transaminases   Adequate renal function Exclusion Criteria:   Bilateral or inflammatory breast cancer (bilateral mammography is required during Screening/baseline); locally recurrent breast cancer   Patients currently receiving systemic therapy for any other malignancy, or having received systemic therapy for a malignancy in the preceding 3 months   Uncontrolled cardiac disease   Patients who are currently receiving chronic treatment (>3 months) with corticosteroids at a dose  10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed), or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug   Impaired GI function that may affect the absorption of LCL161   Pregnant or breast feeding (lactating) women   Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 180 days after study treatment   Other protocol-defined inclusion/exclusion criteria may apply